当前位置：文档库 › 默克公司(Merck)2011年2季度财报

默克公司(Merck)2011年2季度财报

Merck & Co., Inc.

Financial Highlights Package

Second Quarter 2011

Table of Contents

Table 1: GAAP P&L (1)

Table 1a: GAAP P&L – Current Year and Prior Year by Quarter (2)

Table 2a: GAAP to Non-GAAP P&L Reconciliation 2Q11 (3)

Table 2b: GAAP to Non-GAAP P&L Reconciliation Jun YTD 11 (4)

Table 2c: GAAP to Non-GAAP P&L Reconciliation 2Q10 (5)

Table 2d: GAAP to Non-GAAP P&L Reconciliation Jun YTD 10 (6)

Table 3: Sales – Current Year and Prior Year by Quarter (7)

Table 3a: Sales – U.S. / Ex- U.S. 2Q11 (8)

Table 3b: Sales – U.S. / Ex- U.S. Jun YTD 11 (9)

Table 3c: Sales – Pharmaceutical Geographic Split (10)

Table 4: Equity Income / JV Sales / Other (Income) Expense (11)

Supplement to

2Q 2011

Earnings Release

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 1

Sales

12,151

$ 11,346

$ 7%

23,732

$ 22,768

$ 4%

Costs, Expenses and Other Materials and production (1)

4,284 4,549 -6%8,343 9,764 -15%Marketing and administrative (1) / (2)3,525 3,175 11%6,689 6,397 5%Research and development (1) / (2)1,936 2,179 -11%4,094 4,230 -3%Restructuring costs (3)

668

526

27%654

814

-20%Equity income from affiliates (4)(55) (43) 28%(193) (180) 7%Other (income) expense, net (1) / (5)121 (281) *744 (113) *Income Before Taxes

1,672 1,241

35%

3,401 1,856 83%

Income Tax (Benefit) Provision (382) 461

276

746 Net Income

2,054 780

*3,125 1,110 *

Less: Net Income Attributable to Noncontrolling Interests

30 28

59 Net Income Attributable to Merck & Co., Inc.2,024$ 752$ *3,067$ 1,051$ *Earnings per Common Share Assuming Dilution (6)

0.65

$ 0.24

$ *

0.98

$ 0.33

$ *

Average Shares Outstanding Assuming Dilution 3,110

3,125

3,106

3,132

Tax Rate (7)

-22.8%

37.1%

8.1%

40.2%

*> 100%

YTD 2011

YTD 2010

GAAP

2Q102Q11

(7) The GAAP effective tax rates for the second quarter and first six months of 2011 were (22.8)% and 8.1%, respectively, which reflect the net favorable impact of approximately $700 million related to the settlement of the company's 2002-2005 federal income tax audit and the favorable impact of certain foreign and state tax rate changes that resulted in a net $230 million reduction of deferred tax liabilities on intangibles established in purchase accounting. Excluding these items and the other non-GAAP reconciling items detailed in the accompanying tables, the effective tax rates were 24.3% and 24.9% for the second quarter and first six months of 2011, respectively. The GAAP effective tax rates for the second quarter and first six months of 2010 were 37.1% and 40.2%, respectively. Excluding the impact of the non-GAAP reconciling items detailed in the accompanying tables, the effective tax rates were 20.5% and 21.7% for the second quarter and first six months of 2010, respectively.

% Change

(4) Primarily reflects equity income from the AstraZeneca LP, Johnson & JohnsonoMerck Consumer Pharmaceuticals Company, and Sanofi Pasteur MSD partnerships.

(5) Other (income) expense, net in the first six months of 2011 includes a charge of $500 million related to the resolution of the arbitration proceeding with Johnson & Johnson and a $127 million gain on the sale of certain manufacturing facilities and related assets. Other (income) expense, net in the second quarter and first six months of 2010 includes $443 million of income recognized upon AstraZeneca's asset option exercise. In addition, other (income) expense, net in the first six months of 2010 reflects $102 million of income on the settlement of certain disputed royalties.

(6) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and

participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate earnings per common share assuming dilution was $2,020 million and $749 million for the second quarter of 2011 and 2010, respectively, and was $3,059 million and $1,047 million for the first six months of 2011 and 2010, respectively.

(1) Amounts include the impact of acquisition-related costs and restructuring costs. See accompanying tables for details.

(2) The second quarter and first six months of 2010 include a reclassification of certain expenses from marketing and administrative to research and development of

$28 million and $52 million, respectively.

(3) Represents separation and other related costs associated with restructuring activities.

GAAP

% Change

Page 1

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)Table 1a

Sales

11,580$ 12,151$ 23,732$ 11,422$ 11,346$ 22,768$ 11,125$ 12,094$ 45,987

$ 7%

Costs, Expenses and Other Materials and production 4,059 4,284 8,343 5,216 4,549 9,764 4,191 4,440 18,396 -6%-15%Marketing and administrative (1)

3,164 3,525 6,689 3,222 3,175 6,397 3,192 3,537 13,125 11%5%Research and development (1)

2,158 1,936 4,094 2,051 2,179 4,230 2,322 4,559 11,111 -11%-3%Restructuring costs (14) 668 654 288 526 814 50 121 985 27%-20%Equity income from affiliates (138) (55) (193) (138) (43) (180) (236) (171) (587) 28%7%Other (income) expense, net 622 121 744 167

(281) (113) 1,108 309 1,304

**Income (Loss) Before Taxes 1,729 1,672 3,401 616 1,241 1,856 498

(701) 1,653 35%

83%

Income Tax Provision (Benefit)658

(382) 276

286461 746 126 (201) 671 Net Income (Loss)

1,071 2,054 3,125 330 780 1,110 372

(500) 982

Less: Net Income Attributable to Noncontrolling Interests

28 30 58 3128 59 30 31 121

Net Income (Loss) Attributable to Merck & Co., Inc.

1,043$ 2,024$ 3,067$ 299$ 752$ 1,051$ 342$ (531)$ 861$ **Earnings (Loss) per Common Share Assuming Dilution

0.34$ 0.65$

0.98$ 0.09$ 0.24$ 0.33$ 0.11

$ (0.17)$ 0.28

$ *

Average Shares Outstanding Assuming

Dilution 3,104 3,110

3,106 3,141 3,125 3,132 3,102 3,081 3,120

Tax Rate

38.1%

-22.8%

8.1%

46.4%

37.1%

40.2%

25.3%

28.7%

40.6%

Sum of quarterly amounts may not equal year-to-date amounts due to rounding. *> 100%

Full Year

YTD

2011

2Q 2010

(1) Amounts in 2010 include a reclassification of certain expenses from marketing and administrative to research and development of $24 million, $28 million, $26 million,

$42 million and $120 million in 1Q, 2Q, 3Q, 4Q and full year, respectively.

YTD % Change Page 2

SECOND QUARTER 2011

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)Table 2a

Sales

12,151

$ -$ 12,151$ Materials and production 4,2841,344 109 1,453 2,831 Marketing and administrative 3,52577 23 100 3,425 Research and development 1,93619

16 35 1,901 Restructuring costs 668668

668 - Equity income from affiliates (55)- (55) Other (income) expense, net 1217

7 114 Income Before Taxes 1,672(1,440)

(816)

(7)

(2,263) 3,935 Taxes on Income (382)(1,337) (3)

955 Net Income

2,054

(926)

2,980

Less: Net Income Attributable to

Noncontrolling Interests

- 30 Net Income Attributable to Merck & Co., Inc.

2,024$ (926)

$ 2,950$ Earnings per Common Share Assuming Dilution

0.65

$ 0.95

$ (4)

Average Shares Outstanding

Assuming Dilution 3,110

3,110

Tax Rate

-22.8%

24.3%

Non-GAAP

GAAP

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and

trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

Acquisition-Related Costs (1)

Restructuring Costs (2)

Certain Other

Items

Adjustment Subtotal (4) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was $2,942 million for the second quarter of 2011.

(3) Includes a net benefit of approximately $700 million relating to the settlement of the company's 2002-2005 federal income tax audit, the favorable impact of certain foreign and state tax rate changes that resulted in a net $230 million reduction of deferred tax liabilities on intangibles established in purchase accounting, as well as the estimated tax impact on the reconciling items.

(1) Amounts included in materials and production costs reflect expenses of $1.2 billion for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of the merger, as well as $118 million of impairment charges on product intangibles. Amounts included in marketing and administrative expenses reflect integration costs, as well as other costs associated with mergers and acquisitions, such as severance costs which are not part of the company's formal restructuring programs. Amounts included in research and development expenses represent in-process research and development (“IPR&D”) impairment charges.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company's formal restructuring programs.

SIX MONTHS ENDED JUNE 30, 2011

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)Table 2b

Sales

23,732

$ -$ 23,732$ Materials and production 8,3432,641 181 2,822 5,521 Marketing and administrative 6,689135 46 181 6,508 Research and development 4,094321

61 382 3,712 Restructuring costs 654654

654 - Equity income from affiliates (193)- (193) Other (income) expense, net 744373

373 371 Income Before Taxes 3,401(3,097)

(942)

(373)

(4,412) 7,813 Taxes on Income 276(1,668) (4)

1,944 Net Income

3,125

(2,744)

5,869

Less: Net Income Attributable to

Noncontrolling Interests

- 58 Net Income Attributable to Merck & Co., Inc.

3,067$ (2,744)

$ 5,811$ Earnings per Common Share Assuming Dilution

0.98

$ 1.87

$ (5)

Average Shares Outstanding

Assuming Dilution 3,106

3,106

Tax Rate

8.1%

24.9%

Certain Other Items (3)

(1) Amounts included in materials and production costs reflect expenses of $2.5 billion for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of the merger, as well as $118 million of impairment charges on product intangibles. Amounts included in marketing and administrative expenses reflect integration costs, as well as other costs associated with mergers and acquisitions, such as severance costs which are not part of the company's formal restructuring programs. Amounts included in research and development expenses represent in-process research and development (“IPR&D”) impairment charges.

Acquisition-Related Costs (1)

Adjustment Subtotal (5) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was $5,795 million for the first six months of 2011.

Non-GAAP

GAAP

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and

Restructuring Costs (2)

(3) Included in other (income) expense, net is a $500 million charge related to the resolution of the arbitration proceeding with Johnson & Johnson and a $127 million gain on the sale of certain manufacturing facilities and related assets.

(4) Includes a net benefit of approximately $700 million relating to the settlement of the company's 2002-2005 federal income tax audit, the favorable impact of certain foreign and state tax rate changes that resulted in a net $230 million reduction of deferred tax liabilities on intangibles established in purchase accounting, as well as the estimated tax impact on the reconciling items.

SECOND QUARTER 2010

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)Table 2c

Sales

11,346$ -$ 11,346$ Materials and production 4,549 1,662 224

1,886 2,663 Marketing and administrative 3,175 75

75 3,100 Research and development 2,179 144 144 2,035 Restructuring costs 526 526 526 - Equity income from affiliates (43) - (43) Other (income) expense, net (281) 10 (443) (433) 152 Income Before Taxes 1,241 (1,747)

(894)

443

(2,198) 3,439 Taxes on Income 461 (242) (4)

703 Net Income

780 (1,956) 2,736 Less: Net Income Attributable to

Noncontrolling Interests

28 - 28 Net Income Attributable to Merck & Co., Inc.

752$ (1,956)

$ 2,708$ Earnings per Common Share Assuming Dilution

0.24

$ 0.86

$ (5)

Average Shares Outstanding Assuming Dilution 3,125

3,125

Tax Rate

37.1%

20.5%

(3) Included in other (income) expense, net is $443 million of income recognized upon AstraZeneca's asset option exercise.(4) Represents the estimated tax impact on the reconciling items.

(5) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was $2,697 million for the second quarter of 2010.

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of the merger. Amounts included in marketing and administrative expenses and other (income) expense, net reflect transaction and integration costs associated with mergers and acquisitions.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be sold or closed related to actions under the company's formal restructuring programs.

Non-GAAP

GAAP

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and

Acquisition-Related Costs (1)

Restructuring Costs (2)

Certain Other Items (3)

Adjustment Subtotal

SIX MONTHS ENDED JUNE 30, 2010

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)Table 2d

Sales

22,768$ -$ 22,768$ Materials and production 9,764 4,009 281

4,290 5,474 Marketing and administrative 6,397 154 154 6,243 Research and development 4,230 27

150 177 4,053 Restructuring costs 814 814 814 - Equity income from affiliates (180) - (180) Other (income) expense, net (113) 17 (443) (426) 313 Income Before Taxes 1,856 (4,207)

(1,245)

443

(5,009) 6,865 Taxes on Income 746 (745) (4)

1,491 Net Income

1,110 (4,264) 5,374 Less: Net Income Attributable to

Noncontrolling Interests

59 - 59 Net Income Attributable to Merck & Co., Inc.

1,051$ (4,264)

$ 5,315$ Earnings per Common Share Assuming Dilution

0.33

$ 1.69

$ (5)

Average Shares Outstanding Assuming Dilution 3,132

3,132

Tax Rate

40.2%

21.7%

(4) Includes a charge of $147 million associated with a change in tax law enacted as part of U.S. health care reform legislation, as well as the estimated tax impact on the reconciling items. (3) Included in other (income) expense, net is $443 million of income recognized upon AstraZeneca's asset option exercise.

(5) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security

holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was $5,293 million for the six months ended June 30, 2010.

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of the merger. Amounts included in research and development expenses represent in-process research and development (“IPR&D”) impairment charges. Amounts included in marketing and administrative expenses and other (income) expense, net reflect transaction and integration costs associated with mergers and acquisitions.

Non-GAAP

GAAP

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and

Acquisition-Related Costs (1)

Restructuring Costs (2)

Certain Other Items (3)

Adjustment Subtotal

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES

(AMOUNTS IN MILLIONS)

Table 3

Jun YTD

TOTAL SALES (1)$11,580$12,151$23,732$11,422$11,346$22,768$11,125$12,094$45,98774PHARMACEUTICAL (2)

9,82010,36020,1799,6659,63819,3039,52310,44139,26775Cardiovascular Zetia 5825921,1745345641,0985716292,29757Vytorin 4804599394774909674855622,014-6-3Integrilin

645612070701406363266-20-14Diabetes & Obesity Januvia 7397791,5185116001,1116006752,3853037Janumet

3053216262012184192472889544750Diversified Brands Cozaar / Hyzaar 4264068327824851,2674234152,104-16-34Zocor 127107234116117233114121468-9--Propecia 106112218100113213109124447-13Claritin Rx 12065186985815753862961219Remeron

605711751591105062223-46Vasotec / Vaseretic 575911659631226964255-6-5Proscar

5311358561145844216-5-1Infectious Disease Isentress 2923376292322674992783131,0902626Cancidas 158168326153150303135174611128PegIntron 166154319186185371168198737-17-14Primaxin 136136272159158317135158610-13-14Invanz 871031897583158911133622420Avelox 1066116710659165599231631Noxafil 555611049509952481981212Rebetol 534810056551115554221-13-10Crixivan / Stocrin 455095524810049582064-5Neurosciences & Ophthalmology Maxalt

173131304135133268133149550-114Cosopt / Trusopt 114122236115123238114131484-1-1Oncology Temodar 2482344812742715452542661,065-14-12Emend 871202078493177911103782917Intron A

479654511055054209-7-9Respiratory & Immunology Singulair 1,3281,3542,6821,1651,2582,4231,2151,3494,987811Remicade 7538421,5956746691,3436617102,7142619Nasonex 3733236963203386582593031,219-46Clarinex 15520936416419135513113862393Arcoxia 114100214959519094115398512Simponi 5475129101828274297**Asmanex 604710751561074853208-16-1Proventil 42378057551124355210-32-29Dulera 132537000268**Vaccines

ProQuad, M-M-R II and Varivax 2442915353193406594342851,378-14-19Gardasil 214277490233219451316221988279RotaTeq 12514827293139231119169519718Zostavax 24122146951811423107243*28Pneumovax

79641435159110110156376829Women's Health & Endocrine Fosamax 208221429230241472220234926-9-9NuvaRing 14215429713514528013414555966Follistim AQ 13314327613413727011913852842Implanon 6081141515110164712366039Cerazette

5966125554910456492093420Other Pharmaceutical (3)7459481,6979469411,8889421,0443,8791-10ANIMAL HEALTH 7588021,5607097311,4406878152,941108CONSUMER CARE (2)

5175411,0584895441,0324093811,823-12Claritin OTC 167134301136167303120103526-19-1Other Revenues (4)

4864489355594339935064571,9563-6Astra

322

306

628

364

241

605

345

302

1,252

* 100% or greater

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.(1)

Only select products are shown. 2Q

(2)

Beginning in 2011, Merck changed the reporting for certain over-the-counter products. Sales of these products outside the United States were previously recorded in the Pharmaceutical business, and are now reported in the Consumer Care business. Prior period amounts have been recast on a comparative basis.

(3)

Includes pharmaceutical products not individually shown above. Other vaccines sales included in Other Pharmaceutical were $54 million and $67 million for the first and second quarters of 2011, respectively. Other vaccines sales included in Other Pharmaceutical were $55 million, $57 million, $94 million and $75 million for the first, second, third and fourth quarters of 2010, respectively.

(4)

Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

% Change % Change

2011

Full Year Jun YTD Jun YTD

2010

Page 7

Table 3a

2Q11

2Q10 % Change

2Q112Q10 % Change

TOTAL SALES

(1)

$12,151$11,3467$5,006$4,8643$7,145$6,48210PHARMACEUTICAL (2)

10,3609,63874,0884,026

26,2715,61212Cardiovascular Zetia 5925645292308 -5300

25617Vytorin 459490-6215263 -192442278Integrilin

5670-205165 -225510Diabetes & Obesity Januvia 77960030423380 1135622062Janumet

32121847

173

136 271498281Diversified Brands Cozaar / Hyzaar 406485-1614 63 -77392423-7Zocor 107117-99 9 -298108-9Propecia 112113-13337 -1079773Claritin Rx 655812655812Remeron

5759-412 -385557-3Vasotec / Vaseretic 5963-6

5963-6Proscar

56-51 2 -525254-4Infectious Disease Isentress 33726726171130 3116613721Cancidas 16815012614 -5516113519PegIntron 154185-171025 -62144159-10Primaxin 136158-132632 -17110125-12Invanz 10383245143 18524030Avelox 615935555 16523Noxafil 5650121215 -19443525Rebetol 4855-134855-13Crixivan / Stocrin 5048412 -2048465Neurosciences & Ophthalmology Maxalt

131133-18293 -12494022Cosopt / Trusopt 122123-154 14117119-2Oncology Temodar 234271-1496103 -7138168-18Emend 12093296054 11603954Intron A

51-72429 -1824229Respiratory & Immunology Singulair 1,3541,2588869830 548542714Remicade 8426692684266926Nasonex 323338-4148196 -2417514223Clarinex 209191953

-11

15613218Arcoxia 100955100955Simponi 7518*7518*Asmanex 4756-164254 -23

52*Proventil 3755

-323653

-321

-40

Dulera 25*25*Vaccines

ProQuad, M-M-R II and Varivax 291340-14270323 -16211726Gardasil 27721927198163 22795641RotaTeq 1481397120118 2282133Zostavax 12218*12018 *1*Pneumovax

645984749 -4171163Women's Health & Endocrine Fosamax 221241-91521 -31206220-6NuvaRing 15414569088 2645713Follistim AQ 14313743843 -111049411Implanon 8151603319

78483250Cerazette

664934664934Other Pharmaceutical (3)

948941117412737776813-5ANIMAL HEALTH 80273110161153564157811CONSUMER CARE

(2)

541544-1364381

-41771638Claritin OTC 134167-1993124-254143-3Other Revenues

(4)

44843333933052955

129

-57

Astra

306

241

306

241

* 100% or over

(2)

In the first quarter of 2011, Merck changed the reporting for certain over-the-counter products. Sales of these products outside the United States were previously recorded in the Pharmaceutical business, and are now reported in the Consumer Care business. Prior period amounts have been recast on a comparative basis.

(3)

Includes Pharmaceutical products not individually shown above. Other Vaccine sales included in Other Pharmaceutical were $67 million and $57 million on a global basis for second quarter 2011 and 2010, respectively.

(4)

Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

International

Global

U.S.

(1) Only select products are shown.

Table 3b

Jun YTD 2011

Jun YTD 2010

% Change Jun YTD 2011

Jun YTD 2010

% Change Jun YTD 2011

Jun YTD 2010

% Change TOTAL SALES (1)$23,732$22,7684$9,854$9,862$13,877$12,9078PHARMACEUTICAL (2)

20,17919,30357,996

8,098

-1

12,18411,2059Cardiovascular Zetia 1,1741,0987590588 58450915Vytorin 939967-3462518 -11

4774496Integrilin

120140-14110130 -1610103Diabetes & Obesity Januvia 1,5181,11137849734 1666937778Janumet

62641950

335261

2929115884Diversified Brands Cozaar / Hyzaar 8321,267-3451 354 -86781913-14Zocor 234233--17 19 -112172141Propecia 21821336572 -101541419Claritin Rx 1861571918615719Remeron

117110643 21131066Vasotec / Vaseretic 116122-5

116122-5

Proscar

113

114-12 3 -25111111Infectious Disease

Isentress 62949926321241 3330925820Cancidas 32630381929 -3730727312PegIntron 319371-142751 -47292320-9Primaxin 272317-145267 -23221249-11Invanz 189158209581 17947723Avelox 1671651152156 -215969Noxafil 11099122827 2837215Rebetol 100111-10100111-10Crixivan / Stocrin 95100-53

-329295-4Neurosciences & Ophthalmology Maxalt

30426814214176 229092-2

Cosopt / Trusopt 236238-1910 -14227228Oncology Temodar 481545-12198195 1283350-19

Emend 20717717111105 5967134Intron A

105-94959 -1747462Respiratory & Immunology Singulair 2,6822,423111,679

1,559

81,00486416Remicade 1,5951,343191,5951,34319Nasonex 6966586305351 -1339130728Clarinex 3643553100109

-9

2652467Arcoxia 2141901221419012Simponi 12928*12928*Asmanex 107107-196103 -7

114*Proventil 80112

-2975109

-304

Dulera 37*37*Vaccines

ProQuad, M-M-R II and Varivax 535659-19495619 -204040Gardasil 4904519349319 101411336RotaTeq 27223118227191 19454013Zostavax 14611428142114 254*Pneumovax

1431102910789 20362169Women's Health & Endocrine Fosamax 429472-92847 -41401425-6NuvaRing 2972806177171 312010910Follistim AQ 27627027684 -91991867Implanon 141101395838

52836331Cerazette

1251042012510420Other Pharmaceutical (3)1,6971,888-10282310-91,4131,578-10ANIMAL HEALTH 1,5601,440832429311

1,2351,1478CONSUMER CARE (2)

1,0581,0322721718

3373147Claritin OTC 301303-122522676

77-1Other Revenues (4)

935993-68137538122

240

-49

Astra

628

605

628

605

* 100% or over

(4)

Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

International

Global

U.S.

(1) Only select products are shown.

(2)

(3)

Includes Pharmaceutical products not individually shown above. Other Vaccine sales included in Other Pharmaceutical were $121 million and $113 million on a global basis for June YTD 2011 and 2010, respectively.

1Q112Q11

1Q102Q10

3Q104Q10Full Year

TOTAL PHARMACEUTICAL $9,820$10,360$20,179$9,665$9,638$19,303$9,523$10,441$39,26775

United States

3,907

4,088

7,996

4,072

4,026

8,098

4,265

4,384

16,748

2-1

% Pharmaceutical Sales

39.8%

39.5%

39.6%

42.1%

41.8%

42.0%

44.8%

42.0%

42.7%

Europe (1)

2,587

2,827

5,413

2,810

2,631

5,441

2,342

2,677

10,459

7--

% Pharmaceutical Sales

26.3%

27.3%

26.8%

29.1%

27.3%

28.2%

24.6%

25.6%

26.6%

Japan

1,164

1,104

2,268

811

902

1,712

855

1,077

3,645

2332

% Pharmaceutical Sales

11.8%

10.7%

11.2%

8.4%

9.4%

8.9%

9.0%

10.3%

9.3%

Latin America

700

743

1,443

659

696

1,355

699

778

2,832

% Pharmaceutical Sales

7.1%

7.2%

7.1%

6.8%

7.2%

7.0%

7.3%

7.5%

7.2%

Asia Pacific

699

779

1,478

561

622

1,183

618

702

2,503

% Pharmaceutical Sales

7.1%

7.5%

7.3%

5.8%

6.5%

6.1%

6.5%

6.7%

6.4%

China 187206393133159292145173611

Eastern Europe/Middle East Africa

358

369

727

375

395

771

353

393

1,516

-7-6

% Pharmaceutical Sales

3.6%

3.9%

4.1%

4.0%

3.7%

3.8%

3.9%

Canada

360

399

759

337

328

665

374

364

1,403

2114

% Pharmaceutical Sales

3.7%

3.9%

3.8%

3.5%

3.4%

3.9%

3.5%

3.6%

Other

161

3724

% Pharmaceutical Sales

0.5%

0.4%

0.2%

0.6%

0.4%

(1) Europe primarily represents all European Union countries and the European Union accession markets.

% Change 2Q % Change YTD

MERCK & CO., INC.

PHARMACEUTICAL GEOGRAPHIC SALES

(AMOUNTS IN MILLIONS)

Jun YTD 10

Table 3c

Jun

YTD 11

EQUITY INCOME FROM AFFILIATES (millions of dollars)

2Q112Q10YTD 2011YTD 2010ASTRAZENECA LP 44$ 40$ 177$ 165$ Other (1)11 3

16 15

TOTAL

$ 43

$ 193

$ 180

$ SANOFI PASTEUR MSD JOINT VENTURE SALES DETAIL (millions of dollars)All sales reported here are end-market JV sales, presented on a "NET" basis.

2Q112Q10YTD 2011YTD 2010GARDASIL

66$ 82

$ 124$ 165

$ OTHER VIRAL VACCINES 29 2348 46ROTATEQ

11 1420 25HEPATITIS VACCINES 10

620 12FLU VACCINES --1 10Other Vaccines

127 112

217 231

TOTAL SANOFI PASTEUR MSD SALES

243

$ 237

$ 430

$ 489

$ OTHER (INCOME) EXPENSE, NET (millions of dollars)

2Q112Q10YTD 2011YTD 2010INTEREST INCOME (51)$ (22)$ (92)$ (34)$ INTEREST EXPENSE

182 185368 366EXCHANGE LOSSES (GAINS)

1 (4)43 76Other, net (1)

(11) (440)425 (521)

TOTAL

121$ (281)$ 744

$ (113)

$ MERCK & CO., INC.

(1)

Other, net in the first six months of 2011 includes a charge of $500 million related to the resolution of the arbitration proceeding with Johnson & Johnson. Other, net in the second quarter and first six months of 2010 includes $443 million of income recognized upon AstraZeneca's asset option exercise.

EQUITY INCOME / JV SALES / OTHER (INCOME) EXPENSE - GAAP

SECOND QUARTER 2011

Table 4

(1)

Primarily reflects results for Sanofi Pasteur MSD and Johnson & JohnsonoMerck Consumer Pharmaceuticals.